New drug combo aims to shrink tumors in Hard-to-Treat breast cancer
NCT ID NCT07544056
First seen May 02, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study tests whether adding a new drug called BEBT-209 to standard chemotherapy can shrink tumors and help people with advanced triple-negative breast cancer live longer. About 446 women aged 18 to 75 with locally advanced or metastatic triple-negative breast cancer will take part. Participants are randomly assigned to receive either BEBT-209 plus two chemo drugs or the chemo drugs alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.